JP2023504249A5 - - Google Patents
Info
- Publication number
- JP2023504249A5 JP2023504249A5 JP2022531001A JP2022531001A JP2023504249A5 JP 2023504249 A5 JP2023504249 A5 JP 2023504249A5 JP 2022531001 A JP2022531001 A JP 2022531001A JP 2022531001 A JP2022531001 A JP 2022531001A JP 2023504249 A5 JP2023504249 A5 JP 2023504249A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- disease
- cancer
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024069557A JP7802850B2 (ja) | 2019-11-28 | 2024-04-23 | 免疫活性化のためのｄｇｋアルファ阻害剤としての置換アミノキノロン類 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19212252.1 | 2019-11-28 | ||
| EP19212252 | 2019-11-28 | ||
| EP20181065 | 2020-06-19 | ||
| EP20181065.2 | 2020-06-19 | ||
| PCT/EP2020/083198 WO2021105117A1 (en) | 2019-11-28 | 2020-11-24 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024069557A Division JP7802850B2 (ja) | 2019-11-28 | 2024-04-23 | 免疫活性化のためのｄｇｋアルファ阻害剤としての置換アミノキノロン類 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023504249A JP2023504249A (ja) | 2023-02-02 |
| JP2023504249A5 true JP2023504249A5 (enExample) | 2024-05-13 |
| JP7523542B2 JP7523542B2 (ja) | 2024-07-26 |
Family
ID=73476184
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022531001A Active JP7523542B2 (ja) | 2019-11-28 | 2020-11-24 | 免疫活性化のためのｄｇｋアルファ阻害剤としての置換アミノキノロン類 |
| JP2024069557A Active JP7802850B2 (ja) | 2019-11-28 | 2024-04-23 | 免疫活性化のためのｄｇｋアルファ阻害剤としての置換アミノキノロン類 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024069557A Active JP7802850B2 (ja) | 2019-11-28 | 2024-04-23 | 免疫活性化のためのｄｇｋアルファ阻害剤としての置換アミノキノロン類 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US12478621B2 (enExample) |
| EP (1) | EP4065574A1 (enExample) |
| JP (2) | JP7523542B2 (enExample) |
| KR (1) | KR20220122637A (enExample) |
| CN (4) | CN119523983A (enExample) |
| AU (1) | AU2020393384A1 (enExample) |
| BR (1) | BR112022010112A2 (enExample) |
| CA (1) | CA3163105A1 (enExample) |
| CL (1) | CL2022001406A1 (enExample) |
| CO (1) | CO2022007005A2 (enExample) |
| CR (1) | CR20220236A (enExample) |
| DO (1) | DOP2022000110A (enExample) |
| EC (1) | ECSP22041839A (enExample) |
| GE (2) | GEP20247646B (enExample) |
| IL (1) | IL293213A (enExample) |
| JO (1) | JOP20220131A1 (enExample) |
| MX (1) | MX2022006466A (enExample) |
| PE (1) | PE20231098A1 (enExample) |
| PH (1) | PH12022551260A1 (enExample) |
| SA (1) | SA522432734B1 (enExample) |
| TW (1) | TWI894183B (enExample) |
| WO (1) | WO2021105117A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12478621B2 (en) * | 2019-11-28 | 2025-11-25 | Deutsches Krebsforschungszentrum | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| IL294148A (en) | 2019-12-23 | 2022-08-01 | Bristol Myers Squibb Co | Substituted quinazolinyl compounds are useful as t-cell activators |
| CA3162979A1 (en) | 2019-12-23 | 2021-07-01 | Upender Velaparthi | Substituted piperazine derivatives useful as t cell activators |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| CN115362003B (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| MX2023014762A (es) * | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| CN117355531A (zh) * | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359413A1 (en) * | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7651018B2 (ja) * | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| CA3228862A1 (en) * | 2021-08-03 | 2023-02-09 | Beigene, Ltd. | Pyrazolopyridinone compounds |
| IL315015A (en) | 2022-03-01 | 2024-10-01 | Insilico Medicine Ip Ltd | Diacylglycerol kinase (DGK) alpha inhibitors and their uses |
| CN117088874A (zh) * | 2022-05-19 | 2023-11-21 | 轩竹生物科技股份有限公司 | 二酰甘油激酶抑制剂及其用途 |
| CN119998295A (zh) | 2022-06-08 | 2025-05-13 | 因赛特公司 | 作为dgk抑制剂的三环三唑并化合物 |
| US12600723B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US12600722B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| JP2025163312A (ja) * | 2022-09-06 | 2025-10-29 | 小野薬品工業株式会社 | ジアシルグリセロールキナーゼαおよび／またはζ阻害活性を有する化合物およびその医薬用途 |
| CN116283803A (zh) * | 2022-12-05 | 2023-06-23 | 上海旭东海普药业有限公司 | 一种氟马西尼中间体的制备方法 |
| TW202436351A (zh) | 2023-02-06 | 2024-09-16 | 德商拜耳廠股份有限公司 | Ccr8抗體及dgk抑制劑之組合 |
| WO2025030002A2 (en) * | 2023-08-02 | 2025-02-06 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| CN122094689A (zh) * | 2023-09-04 | 2026-05-26 | 英矽智能科技知识产权有限公司 | 二酰甘油激酶(DGK)α抑制剂与其他疗法的组合治疗 |
| CN119143671B (zh) * | 2024-11-21 | 2025-05-16 | 九洲药业(杭州)有限公司 | 一种插羰反应一锅法简便合成喹啉酮衍生物的方法 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4435479A1 (de) | 1994-10-04 | 1996-04-11 | Bayer Ag | Chinolon- und Naphthyridoncarbonsäure-Derivate |
| CZ303899B6 (cs) * | 1998-09-29 | 2013-06-19 | Wyeth Holdings Corporation | Substituovaný 3-kyanochinolin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem |
| SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| CA2483314A1 (en) | 2002-04-25 | 2003-11-06 | Pharmacia Corporation | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
| US7884127B2 (en) | 2002-07-08 | 2011-02-08 | Pirimal Life Sciences Ltd. | Inhibitors of cyclin dependent kinases and their use |
| TWI331034B (en) | 2002-07-08 | 2010-10-01 | Piramal Life Sciences Ltd | Inhibitors of cyclin-dependent kinases and their use |
| JP2005170792A (ja) | 2002-11-22 | 2005-06-30 | Mitsubishi Pharma Corp | Ｌ−プロリン誘導体およびその医薬としての用途。 |
| TW200418829A (en) * | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| DE10337191A1 (de) | 2003-08-13 | 2005-03-17 | Bayer Healthcare Ag | Neue Verwendung von Chinolon-Antibiotika |
| US20050239790A1 (en) | 2004-03-09 | 2005-10-27 | Varghese John | Substituted hydroxyethylamine aspartyl protease inhibitors |
| US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
| CA2587489C (en) | 2004-11-03 | 2013-12-31 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| TW200800999A (en) | 2005-09-06 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
| GB0605689D0 (en) | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
| ES2620634T3 (es) | 2008-10-09 | 2017-06-29 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Activadores de piruvato quinasa humana |
| FR2953834B1 (fr) | 2009-12-10 | 2012-01-13 | Galderma Res & Dev | Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique |
| WO2011082285A1 (en) | 2009-12-30 | 2011-07-07 | Avila Therapeutics, Inc. | Ligand-directed covalent modification of protein |
| JP5951600B2 (ja) | 2010-05-21 | 2016-07-13 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | キナーゼ調節のための、化合物、組成物および方法 |
| WO2012009649A1 (en) | 2010-07-16 | 2012-01-19 | Anderson Gaweco | Mif inhibitors and their uses |
| EP2675440B1 (en) | 2011-02-14 | 2020-03-25 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| US9133164B2 (en) | 2011-04-13 | 2015-09-15 | Innov88 Llc | MIF inhibitors and their uses |
| PE20141371A1 (es) * | 2011-08-29 | 2014-10-13 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos |
| JP6318156B2 (ja) | 2012-09-06 | 2018-04-25 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼをモジュレートするための化合物および方法、ならびにその指標 |
| BR122019007990B1 (pt) | 2013-11-18 | 2021-05-04 | Forma Therapeutics, Inc | Composto, e, composição farmacêutica |
| US9273067B2 (en) | 2014-02-19 | 2016-03-01 | Bristol-Myers Squibb Company | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| US10357484B2 (en) | 2015-07-17 | 2019-07-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US10376504B2 (en) | 2015-07-29 | 2019-08-13 | Merck, Sharp & Dohme Corp. | Substituted quinolinones as PDE9 inhibitors |
| WO2017101763A1 (en) | 2015-12-13 | 2017-06-22 | Hangzhou Innogate Pharma Co., Ltd. | Heterocycles useful as anti-cancer agents |
| MX2021006804A (es) | 2015-12-17 | 2023-01-13 | Merck Patent Gmbh | Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios. |
| US10604505B2 (en) | 2016-03-15 | 2020-03-31 | Natco Pharma Limited | Modified process for the preparation of Ceritinib and amorphous form of Ceritinib |
| CN109575016B (zh) | 2017-09-28 | 2022-01-04 | 药捷安康(南京)科技股份有限公司 | Pde9抑制剂及其用途 |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| JP2021506862A (ja) | 2017-12-19 | 2021-02-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 |
| AU2019284472B2 (en) | 2018-06-11 | 2024-05-30 | Amgen Inc. | KRAS G12C inhibitors for treating cancer |
| CN112654621B (zh) | 2018-06-27 | 2024-05-14 | 百时美施贵宝公司 | 可作为t细胞活化剂的经取代萘啶酮化合物 |
| SG11202012973RA (en) | 2018-06-27 | 2021-01-28 | Bristol Myers Squibb Co | Naphthyridinone compounds useful as t cell activators |
| SG11202100818RA (en) | 2018-07-31 | 2021-02-25 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| WO2020143626A1 (zh) | 2019-01-08 | 2020-07-16 | 南京药捷安康生物科技有限公司 | Pde9抑制剂及其用途 |
| CN111471059B (zh) | 2019-01-23 | 2022-12-02 | 药捷安康(南京)科技股份有限公司 | Pde9抑制剂及其用途 |
| CN111484477B (zh) | 2019-01-29 | 2022-07-08 | 博瑞生物医药（苏州）股份有限公司 | 一种苯并吡啶酮杂环化合物及其用途 |
| TWI816026B (zh) | 2019-03-08 | 2023-09-21 | 大陸商藥捷安康(南京)科技股份有限公司 | 磷酸二酯酶抑制劑的用途和藥盒 |
| US20220340597A1 (en) | 2019-04-09 | 2022-10-27 | Hoffmann-La Roche Inc. | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| US12478621B2 (en) | 2019-11-28 | 2025-11-25 | Deutsches Krebsforschungszentrum | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| WO2021105115A1 (en) | 2019-11-28 | 2021-06-03 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| EP4065584A1 (en) | 2019-11-28 | 2022-10-05 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
-
2020
- 2020-11-24 US US17/780,890 patent/US12478621B2/en active Active
- 2020-11-24 AU AU2020393384A patent/AU2020393384A1/en active Pending
- 2020-11-24 MX MX2022006466A patent/MX2022006466A/es unknown
- 2020-11-24 GE GEAP202015986A patent/GEP20247646B/en unknown
- 2020-11-24 WO PCT/EP2020/083198 patent/WO2021105117A1/en not_active Ceased
- 2020-11-24 PH PH1/2022/551260A patent/PH12022551260A1/en unknown
- 2020-11-24 CN CN202411475042.0A patent/CN119523983A/zh active Pending
- 2020-11-24 IL IL293213A patent/IL293213A/en unknown
- 2020-11-24 KR KR1020227021418A patent/KR20220122637A/ko not_active Ceased
- 2020-11-24 CN CN202411475048.8A patent/CN119564686A/zh active Pending
- 2020-11-24 CA CA3163105A patent/CA3163105A1/en active Pending
- 2020-11-24 JP JP2022531001A patent/JP7523542B2/ja active Active
- 2020-11-24 CN CN202411475034.6A patent/CN119424429A/zh active Pending
- 2020-11-24 CR CR20220236A patent/CR20220236A/es unknown
- 2020-11-24 CN CN202080094610.6A patent/CN115003665B/zh active Active
- 2020-11-24 EP EP20808438.4A patent/EP4065574A1/en active Pending
- 2020-11-24 BR BR112022010112A patent/BR112022010112A2/pt unknown
- 2020-11-24 GE GEAP202415986A patent/GEAP202415986A/en unknown
- 2020-11-24 PE PE2022000967A patent/PE20231098A1/es unknown
- 2020-11-27 TW TW109141886A patent/TWI894183B/zh active
-
2022
- 2022-05-25 CO CONC2022/0007005A patent/CO2022007005A2/es unknown
- 2022-05-25 SA SA522432734A patent/SA522432734B1/ar unknown
- 2022-05-25 EC ECSENADI202241839A patent/ECSP22041839A/es unknown
- 2022-05-25 DO DO2022000110A patent/DOP2022000110A/es unknown
- 2022-05-26 JO JOP/2022/0131A patent/JOP20220131A1/ar unknown
- 2022-05-27 CL CL2022001406A patent/CL2022001406A1/es unknown
- 2022-11-30 US US18/072,490 patent/US11998539B2/en active Active
-
2024
- 2024-04-23 JP JP2024069557A patent/JP7802850B2/ja active Active